[Antitumor effects of a podophyllotoxin derivative, XXXX ].

@entity242 @entity19 @entity5 @entity1138 @entity2 @entity786 @entity900 @entity2879 @entity3600 @entity6844 @entity8270
Single and combination chemotherapies of @entity2879 , a new antitumor agent were evaluated for its antitumor effect against several @entity19 @entity5 . Dose-dependent antitumor effects were observed when @entity2879 was administered via any of the three routes, i.p., i.v. and orally, on days 1 and 5 after i.p. or s.c. inoculation of @entity8270 and @entity242 180. The drug also proved effective against i.v. inoculated EL-LP-12 (subline of @entity8270 ), i.p. or s.c. inoculated P388 and @entity6844 , i.p. inoculated colon 26, and s.c. inoculated colon 38 and @entity2 . However, oral administration of the drug was not effective against @entity6844 , colon 26 and @entity2 despite the fact that the doses employed for this route was higher than those employed for i.v. and i.p. routes. The optimum dosing schedule was also investigated with oral administration of the drug against s.c. inoculated @entity8270 . A single dose (day 1) or two doses (days 1 and 5) were more effective than three doses (days 1, 3 and 5) or five consecutive daily doses. @entity2879 showed additive and more than additive effects in combination with the antitumor agents, @entity786 , @entity3600 , @entity1138 or @entity900 against s.c. inoculated @entity8270 and i.v. inoculated EL-LP-12.
